BAC has entered into a collaboration with LFB Biotechnologies, a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products
Working with LFB, BAC will discover and develop a custom CaptureSelect ligand for the purification of a recombinant Factor VIIa product - an essential protein for certain blood coagulation disorders - developed by LFB with GTC Biotherapeutics.
The CaptureSelect ligand has the potential to obtain high purity in downstream processing while enhancing the cost reduction benefits of the transgenic expression system developed by LFB and GTC.
LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation.
BAC has a proven reputation for the rapid discovery and development of customised ligands for a wide range of affinity applications from the purification of monoclonal antibodies and viruses, to plasma proteins.
The CaptureSelect ligands are suitable and available for use at commercial biomanufacturing scale and for bench research.
"Our expertise in the custom design of affinity ligands makes BAC a great match for LFB in this project," commented Laurens Sierkstra, CEO of BAC.
"Our technology platform enables us to produce ligands that are not only highly specific for the target protein, but will generate a very pure product in a single purification step.
"We are very much looking forward to working with LFB to develop a ligand for their recombinant Factor VIIa protein that will help to simplify and streamline the purification process".
"This collaboration with BAC for the development of a specific ligand for our recombinant factor VIIa is a significant step for the downstream process of this strategic project" commented Sami Chtourou, director of technology platforms and innovation at LFB Biotechnologies.
"Thanks to the strategic alliance with GTC and the collaboration with BAC, we have assembled all the assets and skills required for the success of our rhFVIIa", stated Christian Bechon, LFB's chairman and chief executive officer.
BAC's CaptureSelect ligand technology is based on unique Camelid single chain antibody fragments, which can be selected for desirable chromatographic characteristics and produced at high-titre in a proprietary S.
cerevisiae strain.
The CaptureSelect ligands are suitable and available for use at commercial biomanufacturing scale and for bench research.
